Ms. Adele Sommerfeld, MBA, M.Sc. – Chief Executive Officer
Ms. Sommerfeld possesses a breadth of experience within the biotechnology industry, spanning over 25 years. She brings significant experience across functional areas including biotechnology equity financing transactions, corporate strategy, strategic partnering, and business development. She started her biotech career by launching a bio-diagnostic company, Diagnostics Inc. for the now, Maxxaim Analytics and later facilitating its acquisition by EDITEK, Inc. a US public company after which she and continued as V.P. Business Development. Ms. Sommerfeld later joined the Business Development Bank of Canada as Director of Venture Capital- Life Sciences. Since, Ms. Sommerfeld has taken on both start-up operational roles as CEO and CFO for start-up biotechs including Tolerotech Inc, an RNAi/gene silencing company and Catalyst Medical Technologies, Inc. She has held corporate finance roles for boutique advisory firms such as Evans & Evans and most recently, Phoenix Corporate Finance. Ms. Sommerfeld has a MBA in marketing and M.Sc. in Molecular Genetics, both from the University of Toronto.
Dr. David Berd – Chief Medical Officer
Dr. Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. He is the inventor of MVAX® and OVAX® and co-founder of AVAX. He has been affiliated with AVAX since its founding, having served as Chief Medical Officer 2005-2008, and acting Chief Medical Officer 2013-2015. As National Director for Immunotherapy at Cancer Treatment Centers of America, Dr. Berd investigated the application of the AC Vaccine® to ovarian cancer. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he conducted clinical research on melanoma immunotherapy. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals alongside dozens of editorials, reviews and abstracts. Throughout his career, he has participated in national and international conferences on melanoma and cancer immunotherapy. Dr. Berd has over 30 publications in the field of immunotherapy and has been invited to lecture on the topic, along with oncology, on numerous occasions, since 2000. Dr. Berd received his B.S. from Pennsylvania State University in 1966 and his M.D. from Jefferson Medical College of Thomas Jefferson University in 1968.
Mr. Henry Schea – Executive Director, Global Quality & Regulatory Affairs
Mr. Schea has been the Executive Director of Global Quality and Regulatory Affairs of the Company since April 2002. Mr. Schea has over 20 years’ experience in research, product development, GMP manufacturing and quality control and assurance, with a focus on cell and gene therapies. From 1981 to 1991, Mr. Schea served in various manufacturing and quality control positions at Amgen. From 1991 through 2001, Mr. Schea developed quality systems for new biotech firms including Gene Medicine and Chimeric Therapies. Mr. Schea received his B.S. in Microbial Genetics from the University of Massachusetts in 1976.